Common Stock, par value $0.00001 per share
- Symbol
- EOLS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Evolus, Inc.
EOLSNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Evolus, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Current securities
Registered securities in this filing
EVOLUS, INC. · 8-K · Filed 2026-11-04
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2026, Evolus, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook • Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Increase of 13% Over the Prior Year, Supported by Double-Digit Growth in Global Toxin Revenue and Expanding Contribution from the Hyaluronic Acid (HA) Gel Portfolio • GAAP Operating Loss of $8.4 Million; Positive Adjusted EBITDA of $1.2 Million for the Third Quarter of 2026, Representing a $4.2 Million Year-Over-Year Improvement and the Fourth Consecutive Quarter of Positive Adjusted EBITDA • Reaffirms Full-Year 2026 Net Revenue Guidance of $330 Million to $337 Million, Reaffirms Adjusted Gross Profit Margin Guidance of 67.0% to 67.5%; Updates Non-GAAP Operating Expense Guidance to $210 Million to $213 Million, While Reaffirming Low- to Mid-Single Digit Adjusted EBITDA Margin Outlook • Reaffirms 2028 Long-Term Financial Outlook Reflecting Total Net Revenue Between $450 Million and $500 Million, Representing a Three-Year CAGR of 15% to 19%, and Adjusted EBITDA Margins of 13% to 15% for 2028 NEWPORT BEACH, Ca…
Open exhibit ↗